An 11-page document from UNAIDS, WHO, and AVAC answers questions about oral pre-exposure prophylaxis (PrEP), addressing issues including safety, eligibility, potential risk compensation, implementation, and cost-effectiveness.
The VOICE trial of tenofovir-based vaginal gel and pills was unable to demonstrate efficacy for HIV prevention because of low adherence to study regimens. This study, published in a September 2014 supplement to the Journal of the International AIDS Society, explores views of and experiences with the use of antiretrovirals for HIV prevention among VOICE participants, their male partners, and community members and examines the implications for adherence.
A webpage provides a description of the FEM-PrEP trial of pre-exposure prophylaxis for HIV prevention among women and links to fact sheets and publications describing the results of the trial and related research.
Part of a series on emerging HIV prevention strategies, this document defines pre-exposure prophylaxis (PrEP), reviews the scientific evidence, and outlines key research, regulatory, and advocacy issues.